

PURPOSE:

To provide instructions for performing Weak D testing using a manual tube technique

PRINCIPLE & CLINICAL SIGNIFICANCE:

Principle

Red blood cells from patients are tested with commercial anti-D reagent to determine if the D antigen is present on the patient's red blood cells. In the presence of D antigen, Anti-D reagents bind to the antigen on sample red blood cells and cause an antigen-antibody reaction visible as red blood cell agglutination. RBCs with weakened D antigen may require incubation with the anti-D reagent or testing through the antiglobulin phase for detection.

Clinical Significance

In some recipients determined to be weak D, the possibility exists that pregnancy or transfusion with D+ RBC containing components could result in the production of an allo anti-D.

POLICY

- Weak D testing is performed on the following specimens when the initial Rh result is negative:
 - Cord blood specimens for determination of maternal Rh immune globulin eligibility of a Rh-negative mother
 - Specimens from donors or potential donors of blood or stem cell components (does not include red blood cell component type confirmation testing)
- Weak D testing may also be utilized for ABO/Rh type discrepancy resolution.
- <u>Complete history check regarding prior Rh D typing and transfusion history must be</u> performed in LIS, blood supplier and other hospitals prior to resolution of discrepancy
- For newly identified weak D positive perinatal females:
 - Send the sample to reference lab for weak D type 1,2,3, genotype evaluation
 Notify the TSL MD on-call 8 am to 5 pm to determine the need for Rh immune
 - globulin.

SPECIMEN REQUIREMENTS:

EDTA is preferred and if not tested soon after collection, should be stored at 1-6°C Red top clotted blood samples are also acceptable. See SOP Specimen Acceptability and Order Receipt

REAGENTS/SUPPLIES/EQUIPMENT:

Reagents:	Supplies:	Equipment:
Anti-D	 12 x 75 glass tubes 	Calibrated Serologic
 ABO + Rh Control 		Centrifuge
Blood Bank Saline		Calibrated Cell washer
		Page 1 of 6

Transfusion Service Laboratory

University of Washington Medical Center, 1959 NE Pacific Street, Seattle, WA 98195

Formatted: Font:

TITLE: Weak D Manual Tube Testing Number: PC-0038.0 <u>32</u>			
Anti-IgGIgG coated control cells	Blood bank transfer pipettes	 37 °C Heat block Agglutination viewer	

QUALITY CONTROL:

Quality Control is performed each day of use.

INSTRUCTIONS:

STEP	ACTION		
	Label tube(s) per SOP Labeling for Manual Testing		
	If initial ABO/Rh test tubes are	Then	
	Available	Use the D tube and patient cell suspension from ABO/Rh typing to continue testing Label one tube for control Go to next step 	
1	Not available	 Label 3 tubes: one for patient red cell suspension, one for control and one for anti-D Prepare an approximate 3-4% patient cell suspension Add the following to the anti-D tube 1 drop of Anti-D Add 1 drop of the patient's cell 	
2	Add 1 drop of the ABO/Rh Control reagent to the control tube		
3			
	Add 1 drop of the 3-4% patient cell suspension to the control tube		
4	Mix and incubate the anti-D and control tubes at 37°C ± 1 for 15-30 minutes		
5	Wash tubes 3 times with blood bank saline		
6	Add 2 drops of anti-IgG to each tube		
7	Mix and centrifuge		
8	Resuspend the cell buttons gently, and examine for agglutination		
9	Read, grade, and record the reactions		
10	Add 1 drop of IgG Coated Control Cells to all negative tests		
11	Mix and centrifuge		
12	Read, grade, and record the results		
13	Go to section" Interpreting & Reporting Results"		

Transfusion Service Laboratory University of Washington Medical Center, 1959 NE Pacific Street, Seattle, WA 98195 Page 2 of 6

TITLE: Weak D Manual Tube Testing	Number: PC-0038.03 2
-----------------------------------	------------------------------------

CALCULATIONS/INTERPRETATIONS/RESULTS REPORTING/NORMAL VALUES/CRITICAL VALUES

Results Reporting in Sunquest

1

Step				Action			
1	Select the ap	e appropriate patient specimen in "Blood Order Processing" (BOP)					
2	Note: %DU V	Veak D will b reported as n	e automatical	c. Test window, if not pre ly ordered in LIS on pati can be cancelled if not r	ents ≤ 3 days old when		
	Enter the res	ults and inter	pretation				
		lf	•	Interpretation	Sunguest Key		
	Field	DAHG	DUCC				
2	PT	0	+	Negative	N		
3	С	0	+				
	Field	DAHG	DUCC				
	PT	+	ND	Positive	Р		
	C	0	+				
4	Enter the If Weak D	code below: Positive	,	the <u>A</u> dd Spec. Test wind Enter ;WKDP			
	Weak D Negative ;WKDN Select the initial ABO/Rh test and interpret the Rh as follows:						
	Weak D Interpretation		patient is	Rh Interpretation			
	Negative			Rh Negative			
	Positive	÷	^E emale >50 ∕ears old ∕lale non-SCC	Rh Positive			
5 Positive SCCA patients • SCCA patients • Female ≤ 50 years old who a not prognant • Non Prenatal		 Rh Negative Add a PB com WKDP = Patie Case Workup TSL MD on ca additional wor 	nment: ent is weak D positive will be reviewed by all for determination oif kup, Rh D genotyping n of Rh D status e is	-	Formatted: Bulleted + Level: 1 + Aligned at: 0" + Inder at: 0.25"		
	Positive	• F	Prenatal	Rh Negative	nment: WKDP = Patient		

Page 3 of 6

Transfusion Service Laboratory University of Washington Medical Center, 1959 NE Pacific Street, Seattle, WA 98195

TITI F. Week D Menuel Tube Testing	Number:
TITLE: Weak D Manual Tube Testing	PC-0038.032

Step	Action		
			 is weak D positive Add a BBC comment: RHREC = Further D antigen characterization should be done through Rh D genotyping to determine the need for Rhogam. If genotyping is not done or not available, patient is a candidate for Rh Immune globulin. Send the sample to reference lab for weak D type 1,2,3, genotype evaluation Notify the TSL MD on-call 8 am to 5 pm (to determine the need for Rh immune globulin. Document the following in SQ BOP as a BBCS comment: Date and time of notification Name of TSL MD notified
	Positive	Cord Blood - male	Rh Positive
	Positive	Cord Blood - female	 Rh Positive Add a PB comment indicating the following "Consider Rh negative for transfusion purposes Notify the TSL MD on-call 8 am to 5 pm (to determine the need for Rh immune globulin. Document the following in SQ BOP as a BBCS comment: Date and time of notification Name of TSL MD notified

CALIBRATION:

NA

1

PROCEDURE NOTES AND LIMITATIONS:

- Calls from patient providers regarding Rh genotyping should be referred to the TSL MD oncall.
- Resulting the Rh type as positive in a weak D positive patient may result in a QA failure that can be overridden using BBR along with a free text comment indicating the "Patient is weak D positive".
- Mixed-field agglutination should be investigated for possible cause refer to SOP ABO/Rh

Page 4 of 6

Transfusion Service Laboratory University of Washington Medical Center, 1959 NE Pacific Street, Seattle, WA 98195 **Formatted:** List Paragraph, Bulleted + Level: 3 + Aligned at: 1" + Indent at: 1.25"

TITLE: Weak D Manual Tube Testing	Number:
	PC-0038.032

Discrepancy Resolution

- 3-4% suspension of RBCs may be prepared by one of the following:
 - Using volume estimation with comparison to the reagent red cells for visual verification
 - o By adding one drop of packed RBCs to approximately 1-1.5 mL of blood bank saline
- Results are considered invalid and must be repeated if negative reactions do not produce agglutination following the addition of IgG Coated Control Cells

REFERENCES:

.

1

- Technical Manual. Bethesda, MD: AABB Press, current edition
- Standards for Blood Banks and Transfusion Services. Bethesda, MD: AABB Press, current edition

RELATED DOCUMENTS:

SOP Specimen Acceptability and Order Receipt SOP Quality Control for Manual Testing Reagents SOP Labeling Tubes and Gel Cards for Testing SOP Grading Reactions SOP ABO/Rh Manual Tube Testing SOP ABO/Rh Discrepancy Resolution

APPENDICES:

TITLE: Weak D Manual Tube Testing	Number: PC-0038.0 <mark>32</mark>
-----------------------------------	--------------------------------------

UWMC SOP Approval:				
UWMC CLIA Medical Director				
	Andrew Bryan, MD	Date		
	•			
Transfusion Service Manager		Date		
eel liee manager	Nina Sen			
	Nina Sen			
QA Manager		Date		
	Tayler Reeves			
Transfusion Service				
Medical Director		Date		
	Monica Pagano, MD			
UWMC Biennial R	eview:			
		Date		
		Date		

REVISIONS:

I

07/21/2021: Clarification when to notify the TSL MD for consideration of genotyping, Rhogam eligibility, and adding "consider genotyping" comment to test results. Updated related SOPs. 3/1/2023: Updated to clarify weak D policy for non prenatal patients, %DU added as reflex on Rh negative neonatal samples ≤ 3 days old

Page 6 of 6